Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 9, 2001, Pages 4250-4253

  Feldkamp, Joachim ^a   Pascher, Elke ^c   Schott, Matthias ^c   Goretzki, Peter ^a   Seissler, Jochen ^b   Scherbaum, Werner A ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; FAS ANTIGEN; LEVOTHYROXINE; LIOTHYRONINE; THIAMAZOLE; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PRIORITY JOURNAL; SERUM; SUBTOTAL THYROIDECTOMY; TOXIC GOITER;

EID: 0034845820     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.9.7834     Document Type: Article

References (40)

1. Apoptosis in thyroid diseases: A histochemical study
2. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis
3. Apoptosis in autoimmune and non-autoimmune thyroid disease
4. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
5. The Fas death factor
6. Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction
7. + T cells responding to a bacterial superantigen
8. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity
9. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
10. + T cell-mediated cytotoxicity
11. Fas/(CD95)/FasL interactions required for programmed cell death after T-cell activation
12. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues
13. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing
14. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
15. An N-terminal domain shared by Fas/Apo-1/CD95) soluble variants prevents cell death in vitro
16. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
17. Prognostic significance of soluble Fas in the serum of patients with bladder cancer
18. Elevated serum levels of soluble Fas/APO-1 in human immunodeficiency virus-infected individuals
19. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma
20. Serum concentration of soluble Fas in patients with autoimmune thyroid diseases
21. Elevated soluble Fas levels in herpes zoster patients
22. Increased soluble Fas in patients with Graves' disease
23. Serum levels of soluble Fas in patients with Graves' ophtalmopathy
24. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
25. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro
26. Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Graves' disease (GD) and idiopathic myxoedema
27. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor
28. Potential involvement of Fas and its ligand in the pathogenesis of Hashimotos's thyroiditis
29. Fas-mediated apoptosis is inhibited by TSH and iodine in moderate concentrations in primary human thyrocytes in vitro
30. Apoptosis and thyroiditis
31. Fas/Fas ligand-driven T cell apoptosis as a consequence of ineffective thyroid immunoprivilege in Hashimoto's thyroiditis
32. Gen therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for the Fas ligand
33. Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis
34. Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells
35. The role of Fas-mediated apoptosis in thyroid follicular cells
36. Fas and Fas ligand gene expression in autoimmune thyroiditis in BB/W rats
37. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: Correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism
38. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis
39. Triiodothyronine enhances expression of the interleukin-2 receptor α chain
40. Circulating selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in hyperthyroidism